Ascletis Pharma Inc. (1672.HK)

1.060 -0.040 (-3.64%) At close: 04:08PM HKT

Ascletis Pharma Inc.

Building D
12th Floor 198 Qidi Road, HIPARK Xiaoshan District
Hangzhou 311200
China
86 571 8538 9730
https://www.ascletis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 219

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jinzi Jason Wu Ph.D.	Founder, Chairman & CEO	63.37M	N/A	1964
Ms. Hejingdao Wu	Senior VP of Operations & Executive Director	3.14M	N/A	1974
Ms. Yuemei Yan	Senior Vice President of Clinical Development Operations	N/A	N/A	1970
Dr. Kristjan Sigurdur Gudmundsson	Senior Consultant & Head of Discovery	N/A	N/A	1968
Dr. George Zhengzhi Hill	Senior Consultant & Chief Medical Advisor	N/A	N/A	1951
Mr. John P. Gargiulo M.B.A.	Chief Business Officer	N/A	N/A	1960
Mr. Ming Fai Chung CPA	Company Secretary	N/A	N/A	1979

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Corporate governance

Ascletis Pharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.